Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Southeast Asian J Trop Med Public Health ; 1999 ; 30 Suppl 2(): 97-9
Artigo em Inglês | IMSEAR | ID: sea-31082

RESUMO

Hemoglobin (Hb) E is the most prevalent hemoglobinopathy in Southeast Asia. The prevalence of this condition varies from 9-60% of the population in different regions of Thailand and has the highest prevalence the northeast of the country. Neonatal diagnosis of Hb E can be made by detecting the Hb band in cord blood samples at the Hb A2 position using starch gel and cellulose acetate electrophoresis. Our study, performed in Bangkok, in the central part of Thailand, resealed that 182 out of 1,015 cord blood samples (17.9%) contained Hb E in amounts of between 1.9 and 10.0%. The cases who had Hb A, F and E with or without Hb Bart's were initially included in the study. These cases were suspected to have the Hb E trait. One hundred and seven cases (58.89%) were available for follow up and in all of these, Hb E could be detected throughout the study. A sharp increase in the amount of Hb E was observed at the 3 months follow-up appointment. One year follow-up could be made in 72 cases (39.6%) when the percentage of Hb E was around 25%. We conclude that measurement of Hb E in cord blood an easily accessible, simple, practical and sensitive procedure which can be used to study the Hb E hemoglobinopathy which is widely distributed in Thailand and Southeast Asia.


Assuntos
Sangue Fetal/química , Seguimentos , Hemoglobina E/análise , Hemoglobinopatias/epidemiologia , Hemoglobinas Anormais/análise , Humanos , Recém-Nascido , Triagem Neonatal , Prevalência , Tailândia/epidemiologia
2.
Southeast Asian J Trop Med Public Health ; 1997 ; 28 Suppl 3(): 64-8
Artigo em Inglês | IMSEAR | ID: sea-33814

RESUMO

In Thailand, the most common cause of chronic hemolytic anemia is thalassemia hemoglobinopathy. We report here a 10-year-old girl with pyruvate kinase (PK) deficiency who was initially diagnosed to have Hb H disease, like her sister. The patient had a history of neonatal jaundice which required blood exchange transfusion twice and phototherapy. She became anemic and regular blood transfusion was required since the age of 2 1/2 months. She was very anemic compared to her sister and was transfusion dependent. Besides, she never had red cell inclusion bodies, thus re-evaluation was performed. The diagnosis of red cell pyruvate kinase deficiency and the exclusion of Hb H disease was achieved after cessation of blood transfusion for 3 months. The family study also confirmed the diagnosis. The patient is now on high transfusion and iron chelation. She is doing well with mild splenomegaly.


Assuntos
Criança , Eritrócitos/enzimologia , Família , Feminino , Humanos , Piruvato Quinase/efeitos dos fármacos , Tailândia/epidemiologia , Talassemia alfa/epidemiologia
3.
Asian Pac J Allergy Immunol ; 1996 Jun; 14(1): 49-56
Artigo em Inglês | IMSEAR | ID: sea-37078

RESUMO

In this study, neutrophils isolated from asymptomatic HIV positive individuals, patients with AIDS-related complex (ARC), ARC patients receiving zidovudine (AZT) and full-blown AIDS patients were assayed for their opsonophagocytic and intracellular killing activities. Progressively decreasing opsonophagocytosis of C. albicans by neutrophils correlated with increasing severity of the disease in all groups of HIV infected individuals, as compared to neutrophils isolated from healthy controls. The intracellular killing of C. albicans by neutrophils of asymptomatic and ARC patients did not differ significantly from controls. Neutrophils of ARC patients receiving AZT and AIDS patients showed a slightly decreased killing activity in comparison to that of neutrophils from healthy controls.


Assuntos
Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Candida albicans , Citometria de Fluxo , HIV-1 , Humanos , Neutrófilos/imunologia , Proteínas Opsonizantes/imunologia , Fagocitose , Espectrometria de Fluorescência , Zidovudina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA